Summary
Juniper Pharmaceuticals, Inc. (Juniper), formerly Columbia Laboratories, Inc. is technology driven pharmaceutical company. It carries out the development, manufacture, licensing and sale of pharmaceutical products that address unmet medical needs in women's health. The company develops products based on its proprietary bio-adhesive delivery system (BDS) technology. Juniper has developed five BDS vaginal gel products indicated for conditions such as vaginal pH adjustment, vaginal dryness, amenorrhea and progesterone supplementation as part of fertility treatments; and a BDS testosterone buccal product for male hypogonadism. The company also focuses at developing additional pharmaceutical products to address unmet medical needs in women. Juniper is headquartered in Boston, Massachusetts, the US.
Juniper Pharmaceuticals, Inc. (JNP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Juniper Pharmaceuticals, Inc., Medical Devices Deals, 2010 to YTD 2016 9
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Juniper Pharma Acquires Three New Products to its Proprietary Pipeline 12
Partnerships 13
Juniper Pharma Services Enters into Agreement with Crystec Pharma 13
Molecular Profiles Enters Into Co-Development Agreement With Telormedix 14
Molecular Profiles Enters Into Agreement With Onyx Scientific 15
Licensing Agreements 16
Columbia Labs Enters into Licensing Agreement for IVR Technology 16
Columbia Labs Extends Licensing Agreement With Merck Serono For Crinone 18
Columbia Labs Enters Into Licensing Agreement With Invaron Pharma For STRIANT 20
Columbia Labs Enters Into Licensing Agreement With Actient Pharma 21
Columbia Labs Renews Licensing Agreement With Merck Serono 22
Columbia Labs Terminates Licensing Agreement With Ascend Therapeutics For PROCHIEVE 23
Equity Offering 24
Columbia Labs Completes Private Placement Of US$24.53 Million 24
Asset Transactions 25
Lil’ Drug Store Exercises Option to Acquire Rights for Legatrin PM from Columbia Labs for USD2.2 Million 25
Actient Pharma Acquires US Rights Of STRIANT From Columbia Labs 26
Columbia Labs Completes The Sale Of Progesterone Franchise To Watson Pharma 27
Acquisition 29
Columbia Labs Acquires Molecular Profiles For US$25 Million 29
Juniper Pharmaceuticals, Inc. - Key Competitors 31
Key Employees 32
Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34
List of Tables
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Key Facts, 2014 1
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Juniper Pharmaceuticals, Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Juniper Pharmaceuticals, Inc., Medical Devices Deals, 2010 to YTD 2016 9
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Juniper Pharma Acquires Three New Products to its Proprietary Pipeline 12
Juniper Pharma Services Enters into Agreement with Crystec Pharma 13
Molecular Profiles Enters Into Co-Development Agreement With Telormedix 14
Molecular Profiles Enters Into Agreement With Onyx Scientific 15
Columbia Labs Enters into Licensing Agreement for IVR Technology 16
Columbia Labs Extends Licensing Agreement With Merck Serono For Crinone 18
Columbia Labs Enters Into Licensing Agreement With Invaron Pharma For STRIANT 20
Columbia Labs Enters Into Licensing Agreement With Actient Pharma 21
Columbia Labs Renews Licensing Agreement With Merck Serono 22
Columbia Labs Terminates Licensing Agreement With Ascend Therapeutics For PROCHIEVE 23
Columbia Labs Completes Private Placement Of US$24.53 Million 24
Lil’ Drug Store Exercises Option to Acquire Rights for Legatrin PM from Columbia Labs for USD2.2 Million 25
Actient Pharma Acquires US Rights Of STRIANT From Columbia Labs 26
Columbia Labs Completes The Sale Of Progesterone Franchise To Watson Pharma 27
Columbia Labs Acquires Molecular Profiles For US$25 Million 29
Juniper Pharmaceuticals, Inc., Key Competitors 31
Juniper Pharmaceuticals, Inc., Key Employees 32
Juniper Pharmaceuticals, Inc., Subsidiaries 33
List of Figures
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Juniper Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Juniper Pharmaceuticals, Inc., Medical Devices Deals, 2010 to YTD 2016 9
